Fuji Pharma Co
Fuji Pharma Co., Ltd., commonly referred to as Fuji Pharma, is a prominent player in the pharmaceutical industry, headquartered in Japan. Established in 1950, the company has made significant strides in developing innovative healthcare solutions, primarily focusing on prescription pharmaceuticals and over-the-counter products. With a strong operational presence across Asia, Fuji Pharma is renowned for its commitment to quality and research-driven development. The company’s core offerings include a diverse range of therapeutic agents, particularly in the fields of oncology and infectious diseases, distinguished by their efficacy and safety profiles. Fuji Pharma has garnered recognition for its robust market position, consistently achieving milestones that underscore its dedication to advancing healthcare. Through a combination of cutting-edge technology and a patient-centric approach, Fuji Pharma continues to enhance its reputation as a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does Fuji Pharma Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Fuji Pharma Co's score of 7 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Fuji Pharma Co's reported carbon emissions
In 2022, Fuji Pharma Co reported total carbon emissions of approximately 306,558,000 kg CO2e. This figure includes 6,044,000 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources, and 8,153,000 kg CO2e from Scope 2 emissions, representing indirect emissions from the generation of purchased electricity, steam, heating, and cooling. Notably, the company also disclosed significant Scope 3 emissions, amounting to approximately 292,361,000 kg CO2e, which encompass all other indirect emissions that occur in the value chain. In 2021, Fuji Pharma's total emissions were about 12,514,000 kg CO2e, with Scope 1 emissions at 5,261,000 kg CO2e and Scope 2 emissions at 7,253,000 kg CO2e. This indicates a substantial increase in emissions from 2021 to 2022. Despite the lack of specific reduction targets or initiatives disclosed, Fuji Pharma's commitment to addressing climate change is evident through their emissions reporting. The company has not outlined any science-based targets or specific climate pledges, which places them in a broader industry context where many companies are increasingly setting ambitious goals to reduce their carbon footprints.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 5,261,000 | 0,000,000 |
| Scope 2 | 7,253,000 | 0,000,000 |
| Scope 3 | - | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Fuji Pharma Co is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
